MDX-1097 (formerly called IST-1097, now called KappaMab) is a monoclonal antibody therapy that in 2023 has been assessed in a Phase IIb clinical trial in conjunction with lenalidomide and dexamethasone as a treatment for multiple myeloma, a type of white blood cell cancer.[1][2] MDX-1097 was originally developed by scientists at Immune System Therapeutics Ltd.[3] In 2015, Haemalogix Ltd acquired the rights to MDX-1097 and are taking it through clinical testing.[4]
^Hutchinson AT, Jones DR, Raison RL (October 2015). "Preclinical and clinical development of an anti-kappa free light chain mAb for multiple myeloma". Molecular Immunology. 67 (2 Pt A): 89–94. doi:10.1016/j.molimm.2015.04.013. PMID25964097.
